A 2x2 Factorial, Randomized, Multicenter, Single-Blind Evaluation of Intracoronary Abciximab Infusion and Aspiration Thrombectomy in Patients Undergoing Percutaneous Coronary Intervention for Anterior ST-Segment Elevation Myocardial Infarction.

Trial Profile

A 2x2 Factorial, Randomized, Multicenter, Single-Blind Evaluation of Intracoronary Abciximab Infusion and Aspiration Thrombectomy in Patients Undergoing Percutaneous Coronary Intervention for Anterior ST-Segment Elevation Myocardial Infarction.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Abciximab (Primary)
  • Indications Myocardial infarction; Myocardial ischaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms INFUSE-AMI
  • Sponsors Atrium Medical Corporation
  • Most Recent Events

    • 03 May 2013 1-year outcomes announced in an Atrium Medical Corporation media release.
    • 10 Apr 2013 Actual end date Apr 2013 added as reported by ClinicalTrials.gov.
    • 11 Mar 2013 Results presented at the 62nd Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top